The United Kingdom and the United States have announced a significant commercial pact that will ensure no import taxes on British medicine exports going into the American market.
Key Provisions of the Deal
As part of the deal, the UK has committed to boost spending on pharmaceuticals through the NHS. This pledge guarantees that import taxes on these key goods will be held at zero for a duration of three years.
This deal comes after previous statements to dramatically increase duties on patented pharmaceutical imports, with increases mentioned up to 100%.
"This arrangement with the UK strengthens the global environment for cutting-edge drugs and establishes long-overdue balance to American-British pharmaceutical trade," a statement noted.
Trade Impact
Medicines represent one of the the United Kingdom's biggest exports to the United States, which is by far the primary market for leading British pharmaceutical firms.
Trade data reveal that in the year to the end of the third quarter, the UK sold pharmaceutical products worth billions to the US. This amount made up a significant portion of all goods exports in that timeframe.
"This guarantee secures work, stimulates investment and sets the stage for the UK to establish itself as a international leader for medical research," the Business and Trade Secretary stated.
Specific UK Commitments
The pact entails several specific commitments from the UK:
- Revised Affordability Limit: The UK will increase the price threshold at which it deems new medicines to be unaffordable by 25%.
- Boosted Medicine Funding: There is a goal to double overall NHS spending on treatments from 0.3% of the national economy to 0.6% over the following ten-year period.
- Refund Ceiling: The sum drug companies must refund to the NHS to prevent overspending will be limited at 15%. Last year, refunds topped twenty percent.
Recent Tensions
The pact follows a long-running row between the drug companies and the UK government over drug pricing and NHS adoption.
The disagreement were heightened by assertions that American customers were paying a premium for the equivalent treatments than people in the Britain and the EU.
In recent months, several large manufacturing plans in the UK have been delayed or cancelled, while major expansions have been directed toward US facilities.
One official publicly accepted that the NHS needed to invest a greater share on drugs, noting that its budget allocation on drugs had decreased as a percentage of its overall budget over the previous ten-year period.
